# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improveme...
FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, ma...
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest w...
Approval based on results from CheckMate -901, the first Phase 3 trial in this patient population with an immunotherapy-chemo...